Naviter Wealth LLC Raises Stock Holdings in Eli Lilly and Company (NYSE:LLY)

Naviter Wealth LLC grew its holdings in Eli Lilly and Company (NYSE:LLY) by 21.4% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 5,494 shares of the company’s stock after buying an additional 969 shares during the quarter. Naviter Wealth LLC’s holdings in Eli Lilly and Company were worth $4,867,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Abner Herrman & Brock LLC grew its position in shares of Eli Lilly and Company by 1.4% in the first quarter. Abner Herrman & Brock LLC now owns 26,372 shares of the company’s stock valued at $20,517,000 after purchasing an additional 373 shares during the period. Rise Advisors LLC lifted its stake in Eli Lilly and Company by 112.3% in the 1st quarter. Rise Advisors LLC now owns 760 shares of the company’s stock valued at $592,000 after buying an additional 402 shares in the last quarter. Farmers Trust Co. boosted its holdings in Eli Lilly and Company by 19.3% in the 1st quarter. Farmers Trust Co. now owns 494 shares of the company’s stock worth $384,000 after buying an additional 80 shares during the last quarter. Foster Group Inc. increased its stake in Eli Lilly and Company by 3.2% during the 1st quarter. Foster Group Inc. now owns 1,641 shares of the company’s stock worth $1,277,000 after buying an additional 51 shares in the last quarter. Finally, New Hampshire Trust increased its stake in Eli Lilly and Company by 4.1% during the 1st quarter. New Hampshire Trust now owns 714 shares of the company’s stock worth $555,000 after buying an additional 28 shares in the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Eli Lilly and Company Trading Up 1.1 %

NYSE LLY traded up $10.45 during trading hours on Thursday, reaching $926.87. The company had a trading volume of 194,066 shares, compared to its average volume of 2,977,894. The company has a current ratio of 1.11, a quick ratio of 0.87 and a debt-to-equity ratio of 1.74. The stock has a market capitalization of $880.90 billion, a P/E ratio of 136.51, a price-to-earnings-growth ratio of 2.79 and a beta of 0.42. The stock has a 50-day moving average of $919.25 and a 200 day moving average of $855.84. Eli Lilly and Company has a 1-year low of $547.61 and a 1-year high of $972.53.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, August 8th. The company reported $3.92 EPS for the quarter, topping the consensus estimate of $2.64 by $1.28. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. The business had revenue of $11.30 billion during the quarter, compared to analyst estimates of $9.83 billion. As a group, research analysts anticipate that Eli Lilly and Company will post 16.49 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the company. Sanford C. Bernstein began coverage on Eli Lilly and Company in a research note on Thursday. They issued an “outperform” rating and a $1,100.00 price target on the stock. Truist Financial upped their target price on shares of Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the stock a “buy” rating in a report on Thursday, October 10th. Barclays raised their price target on shares of Eli Lilly and Company from $913.00 to $1,025.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 10th. Bank of America upped their price objective on shares of Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the company a “buy” rating in a research note on Friday, August 9th. Finally, Morgan Stanley reissued an “overweight” rating and issued a $1,106.00 target price on shares of Eli Lilly and Company in a research note on Tuesday, August 27th. Three investment analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $986.00.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.